The project began this September and focuses on the first 30 days after hospital discharge for patients with COPD exacerbations.
Hospital del Mar in Barcelona, in collaboration with the medical technology company Tucuvi, has launched a post-discharge follow-up project for patients with Chronic Obstructive Pulmonary Disease (COPD), using clinically validated conversational artificial intelligence. The project, which began this September, focuses on the first 30 days after hospital discharge for patients with COPD exacerbations.
With this initiative, Hospital del Mar aims to transform post-discharge care by ensuring continuous, structured, and sustainable follow-up for COPD patients. The initial phase will pave the way for a system capable of generating real impact by improving access to standardized follow-up for all patients and reducing hospital readmissions—ultimately contributing to greater healthcare efficiency through the combination of technology and organizational innovation.
LOLA: Conversational AI to enhance post-discharge follow-up in COPD
Through this program, Tucuvi’s AI agent LOLA will contact patients by phone to conduct personalized follow-up, detect warning signs, monitor treatment adherence, and facilitate early intervention by healthcare professionals when needed.
As a clinically validated voice agent with natural language processing, LOLA complements the work of healthcare professionals by automating processes and providing key information to support decision-making, without replacing medical or nursing supervision. This technology enables safer, more efficient, and more accessible post-discharge monitoring, aligning with Hospital del Mar’s goals of sustainability and quality of care.
Tucuvi is the first AI-powered medical voice solution certified as a Class IIb medical device in Europe under the Medical Device Regulation (MDR). This certification acknowledges that its technology meets the highest standards of safety and clinical efficacy, allowing its use in complex care settings such as chronic patient follow-up or home care. This achievement is further supported by the recent ISO 13485 certification, recognizing the quality of Tucuvi’s management system as a medical device manufacturer.
The implementation of our conversational AI has a direct impact on improving operational efficiency and the quality of post-discharge follow-up, resulting in greater accessibility and better control of chronic patients. We are proud to collaborate with Hospital del Mar in Barcelona to continue demonstrating the transformative power of artificial intelligence in healthcare, said María González, CEO of Tucuvi.
The implementation of this tool has been made possible thanks to Hospital del Mar’s commitment to advancing the use of new technologies in patient care. The Pulmonology Department has worked closely with Tucuvi to ensure the tool is tailored to its clinical context and delivers maximum impact for patients:
Beyond the specific objectives that will be evaluated at the institutional level, the most relevant goal of this tool is to detect early changes in a patient’s clinical evolution that allow us to intervene and prevent serious complications such as hospital readmissions, explained Dr. Diego Rodríguez, Head of the Pulmonology Department at Hospital del Mar.
The use of LOLA as a working tool will enable the COPD Advanced Practice Nurse to manage time and resources more efficiently, performing remote, automated, and early assessments of patients and their clinical status within the care process, added Mireia Admetlló Papiol, COPD Advanced Practice Nurse at Hospital del Mar.
Read more about the project here: https://www.hospitaldelmar.cat/ca/noticies/view.php?ID=14667
